aripiprazole
Commercial- Indications
- Schizophrenia, Bipolar I disorder, Depression
Company intelligence / Profile preview
Proteus developed the first FDA-cleared "digital pill"—a medication embedded with an ingestible sensor that tracks ingestion events via a wearable patch and mobile app. The flagship product was commercialized as Abilify MyCite® in partnership with Otsuka for schizophrenia. Clinical pilots demonstrated feasibility for improving medication adherence across several chronic conditions. However, widespread adoption was limited by complexity and reimbursement challenges.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Proteus Digital Health.